Company Encyclopedia
View More
name
Lionco
603669.SH
Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sales of pharmaceutical products and medical services in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular, detoxification, anti-tumor, and other products. Lionco Pharmaceutical Group Co.,Ltd. was founded in 2003 and is based in Shannan, China.
3.165 T
603669.SHMarket value -Rank by Market Cap -/-

Financial Score

08/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking161/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-14.88%E
    • Profit Margin-27.49%E
    • Gross Margin84.56%A
  • Growth ScoreB
    • Revenue YoY55.34%A
    • Net Profit YoY-16.28%D
    • Total Assets YoY-0.37%D
    • Net Assets YoY-14.07%E
  • Cash ScoreC
    • Cash Flow Margin-363.76%D
    • OCF YoY55.34%A
  • Operating ScoreD
    • Turnover0.36D
  • Debt ScoreB
    • Gearing Ratio38.79%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lionco: Subsidiary Lionco Pharmaceutical's product, injectable cefazolin sodium, is expected to be selected for national centralized drug procurement

    Lionco announced that its wholly-owned subsidiary Lionco Pharmaceutical's injectable cefazolin sodium product is expected to be selected for the national centralized drug procurement, with an estimated sales revenue of 23.0089 million yuan in 2024, accounting for 6.06% of the company's annual operating income. If the contract is successfully signed, it will help expand the market and enhance brand influence, but there is uncertainty regarding the subsequent contract signing. The company will closely monitor the progress and fulfill its information disclosure obligations

    Zhitong·
    SH
    603669
    -1.58%
    Zhitong·
    SH
    603669
    -1.58%

    The A-share CRO concept sector has seen a surge, with Lionco hitting the daily limit, MeHow rising over 10%, and Haoyuan Pharmaceutical, Boji Pharmaceutical, Medicilon, Sun-Novo, and Heyuan Biotechnology also following suit

    Zhitong·
    SH
    688202
    +1.35%
    SH
    688621
    -0.35%
    SH
    603669
    -1.58%
    Zhitong·
    SH
    688202
    +1.35%
    SH
    688621
    -0.35%
    SH
    603669
    -1.58%

    The chemical pharmaceutical sector continues to rise, with SUNHERE and Lionco hitting the daily limit

    The chemical pharmaceutical sector continues to rise, with SUNHERE and Lionco hitting the daily limit, while Beilu Pharmaceutical, Hanyu Pharmaceutical, Yong'an Pharmaceutical, Xinghao Pharmaceutical, and Hasenlian also follow suit

    Zhitong·
    SH
    603669
    -1.58%
    SZ
    300452
    -0.85%
    Zhitong·
    SH
    603669
    -1.58%
    SZ
    300452
    -0.85%

    CRO concept stocks partially rose, Lionco surged to the daily limit

    CRO concept stocks saw a partial rise, with Lionco hitting the limit up, and Bio-S, Chemspec, JOINN, and Asymchem following suit

    Zhitong·
    SZ
    301096
    -0.17%
    SH
    688602
    +5.56%
    SH
    603127
    +0.47%
    Zhitong·
    SZ
    301096
    -0.17%
    SH
    688602
    +5.56%
    SH
    603127
    +0.47%

    Lionco: Wholly-owned subsidiary receives clinical trial approval notice for acetazolamide sustained-release capsule medication

    Lionco announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. recently obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration's Drug Evaluation Center for Acetazolamide Sustained-Release Capsules. This drug is suitable for the prevention or improvement of symptoms related to acute mountain sickness that may still occur under gradually rising conditions. Currently, there are no other companies in China applying for this product, and Lionco Pharmaceutical has invested research and development expenses of 6.9 million RMB

    Zhitong·
    SH
    603669
    -1.58%
    Zhitong·
    SH
    603669
    -1.58%
    © 2025 Longbridge｜Disclaimer